1. Home
  2. RMT vs ANL Comparison

RMT vs ANL Comparison

Compare RMT & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Royce Micro-Cap Trust Inc.

RMT

Royce Micro-Cap Trust Inc.

HOLD

Current Price

$13.81

Market Cap

722.0M

Sector

Finance

ML Signal

HOLD

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

HOLD

Current Price

$12.29

Market Cap

731.6M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
RMT
ANL
Founded
1993
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
722.0M
731.6M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
RMT
ANL
Price
$13.81
$12.29
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$20.00
AVG Volume (30 Days)
99.6K
289.2K
Earning Date
01-01-0001
04-10-2026
Dividend Yield
7.37%
N/A
EPS Growth
N/A
N/A
EPS
1.49
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$36.02
Revenue Next Year
N/A
N/A
P/E Ratio
$9.04
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.66
$0.88
52 Week High
$13.97
$17.25

Technical Indicators

Market Signals
Indicator
RMT
ANL
Relative Strength Index (RSI) 65.61 46.26
Support Level $10.32 $11.86
Resistance Level $13.97 $12.09
Average True Range (ATR) 0.27 1.33
MACD -0.04 -0.37
Stochastic Oscillator 88.08 31.46

Price Performance

Historical Comparison
RMT
ANL

About RMT Royce Micro-Cap Trust Inc.

Royce Micro-Cap Trust Inc is a diversified closed-end investment company. The company is engaged in investing in micro-cap securities. It invests in the consumer discretionary sector, including diversified consumer services, hotels, household durables, leisure products, and luxury goods. Consumer staples sector, including beverages, food, and staples retailing, food products, and personal products, Energy sector, including energy equipment and services, and oil, gas, and consumable fuels. The company also invests in other sectors, including healthcare, financials, industrials, IT, telecommunications, and materials.

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.

Share on Social Networks: